Ovarian cancer has no reliable routine screening test for the general population, which makes early detection genuinely difficult. When the cancer is caught while still localized, the five-year survival rate is 91.9%. But only about 21.7% of cases are found at that early stage. Most are discovered after the cancer has already spread, when survival drops to 31.5%. Understanding the tools that exist, their limitations, and what actually increases your chances of an early diagnosis can make a real difference.
Why There’s No Routine Screening
The U.S. Preventive Services Task Force recommends against screening asymptomatic women who don’t have a known high-risk hereditary cancer syndrome. That recommendation surprises many people, but the reasoning is straightforward: the two main screening tools, transvaginal ultrasound and a blood test called CA-125, haven’t been shown to reduce ovarian cancer deaths when used on the general population. Worse, they produce a high rate of false positives, meaning many women without cancer end up undergoing unnecessary surgeries. The positive predictive value of these tests in average-risk women is simply too low to justify widespread use.
This doesn’t mean these tools are useless. It means they work best when applied to women who already have symptoms or who carry specific genetic risk factors, not as blanket screening for everyone.
Symptoms That Should Prompt Investigation
Ovarian cancer does produce symptoms in its early stages, but they mimic common, harmless conditions, which is why they’re so often dismissed. The four most recognized warning signs are bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency. The key distinction is persistence: if you experience any of these symptoms more than 12 times in a single month, that pattern warrants medical evaluation. Occasional bloating after a big meal is normal. Daily bloating that doesn’t resolve is not.
These symptoms overlap with irritable bowel syndrome, urinary tract infections, and menstrual changes, which is exactly why they get overlooked. Paying attention to the frequency and duration, rather than the symptom itself, is what separates a routine complaint from a potential red flag.
Transvaginal Ultrasound
When ovarian cancer is suspected, a transvaginal ultrasound is typically the first imaging test performed. A small probe inserted into the vagina produces detailed images of the ovaries, and it can distinguish between a fluid-filled cyst (usually harmless) and a solid mass (more concerning). The test also reveals features like size, internal structure, and whether a mass has irregular walls or mixed solid-and-fluid components, all of which help a doctor assess how worrisome a finding is.
Ultrasound is painless, takes about 15 to 20 minutes, and doesn’t involve radiation. It’s a strong first step, but it can’t confirm cancer on its own. Many abnormal-looking masses turn out to be benign, and some early cancers can look deceptively normal on imaging.
Blood Tests: CA-125 and HE4
CA-125 is a protein that tends to be elevated in the blood of women with ovarian cancer. Levels above 35 units per milliliter are generally considered irregular. The problem is that CA-125 rises in many non-cancerous conditions too: endometriosis, uterine fibroids, pelvic inflammatory disease, liver disease, and even normal menstruation or pregnancy. This low specificity limits its usefulness as a standalone early detection tool, particularly in premenopausal women where these conditions are common.
A newer blood marker called HE4 has shown promise in complementing CA-125. Research from the Janus Serumbank in Norway found that HE4 levels were detectably elevated in women’s blood roughly two years before their ovarian cancer diagnosis, while CA-125 showed elevations up to four years before diagnosis. Used together, these two markers give clinicians a more complete picture than either one alone.
The ROMA Score
Doctors sometimes combine CA-125, HE4, and a woman’s menopausal status into a calculation called the Risk of Ovarian Malignancy Algorithm, or ROMA. For detecting the most common type of ovarian cancer (epithelial), ROMA achieves a sensitivity of about 78% and a specificity near 89%. In practical terms, that means it correctly flags roughly 8 out of 10 women who do have cancer while correctly clearing about 9 out of 10 who don’t. It’s a useful triage tool for deciding whether a pelvic mass needs urgent specialist referral or routine follow-up, though it’s not a population-wide screening test.
How High-Risk Women Are Monitored
Women with BRCA1 or BRCA2 gene mutations face a significantly higher lifetime risk of ovarian cancer. For these women, the CDC notes that screening with transvaginal ultrasound and CA-125 blood tests is part of ongoing surveillance. This monitoring typically begins earlier in life than cancer screening would for average-risk women, and it happens at regular intervals determined by a genetics specialist or gynecologic oncologist.
Beyond screening, many high-risk women ultimately choose preventive surgery to remove the ovaries and fallopian tubes, often after they’ve finished having children. This remains the most effective risk-reduction strategy for women with hereditary cancer syndromes. Genetic counseling can help clarify your personal risk level and guide these decisions.
Why Surgery Replaces Needle Biopsy
With most cancers, a needle biopsy is the standard way to confirm a diagnosis. Ovarian cancer is different. Doctors generally avoid piercing an ovarian mass with a needle before surgery because of the small risk of tumor seeding, where cancer cells get dislodged and spread along the needle’s track. While studies show this risk is low (under 1% in many cancer types), the consequences of spilling ovarian cancer cells into the abdominal cavity are serious enough that surgeons prefer to remove the entire mass intact.
This means ovarian cancer is usually diagnosed and staged during the same surgery. A gynecologic oncologist removes the suspicious tissue, examines it under a microscope, and checks whether cancer has spread to nearby structures, all in one procedure. The advantage is a definitive answer and immediate treatment. The drawback is that it’s a significant operation, which is why doctors work to identify who truly needs surgery beforehand using imaging and blood markers.
What the Diagnostic Timeline Looks Like
Once ovarian cancer is suspected, things typically move quickly. In the UK’s National Health Service, the target is for patients to receive a cancer diagnosis or exclusion within 28 days of referral. Initial testing, including ultrasound and blood work, is expected within the first nine days. While timelines vary by country and healthcare system, the general principle is the same: a suspected ovarian mass gets fast-tracked.
In practice, the process usually follows a clear sequence. Your doctor orders a transvaginal ultrasound and CA-125 blood test based on your symptoms or a physical exam finding. If results are concerning, you’re referred to a gynecologic oncologist. Additional imaging, such as a CT scan, may follow to assess the extent of any abnormality. If surgery is recommended, the mass is removed and sent for pathology, which provides the definitive diagnosis and stage.
What You Can Actually Do
Given the lack of a reliable screening test, early detection of ovarian cancer relies heavily on two things: knowing your body and knowing your risk. Track persistent symptoms, especially the bloating, pelvic pain, appetite changes, and urinary urgency pattern described above. If they’re new, unexplained, and happening most days of the month, bring them up with your doctor explicitly and mention ovarian cancer by name. Studies consistently show that women who advocate for further testing when symptoms persist are diagnosed at earlier stages.
If you have a family history of ovarian, breast, or related cancers, ask about genetic counseling and testing for BRCA and other hereditary mutations. Identifying high-risk status opens the door to the more intensive monitoring that average-risk women don’t have access to, and it puts you in the group where screening tools actually perform well enough to catch cancer early.